Increased p53 Protein Expression in Malignant Mammary Phyllodes Tumors

• Published in: Modern pathology 2002-07, Vol.15 (7), p.734-740
• Main Authors: Tse, Gary M K, Putti, Thomas C, Kung, Fred Y L, Scolyer, Richard A, Law, Bonita K B, Lau, Tai-shing, Lee, C Soon
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Age Factors; Breast; Breast Neoplasms - diagnosis; Breast Neoplasms - metabolism; Humans; Immunohistochemistry; Laboratory Medicine; Malignant; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Recurrence, Local; original-article; p53; Pathology; Phyllodes tumor; Phyllodes Tumor - diagnosis; Phyllodes Tumor - metabolism; Prognosis; Protein expression; Proteins; Tumor Suppressor Protein p53 - biosynthesis; Tumors
• ISSN: 0893-3952; 1530-0285
• DOI: 10.1097/01.MP.0000018978.75312.5C

The authors reviewed 143 cases (87 benign, 37 borderline, and 19 malignant) of mammary phyllodes tumors (PTs) and used immunohistochemistry to detect p53 protein product semi-quantitatively as negative, weak, moderate and strong (scored 0 to 3). For all PTs, an increasing trend of tumor size and malignancy was detected with increasing age. For p53 staining, 60 cases (42%) were negative, 55 (38%) stained weakly, 28 (13%) stained moderately, and 10 (7%) stained strongly. Of the 87 benign PTs, 41 (47%) were negative, 37 (43%) stained weakly, and 9 (10%) stained moderately. For the 37 borderline PTs, 16 (43%) were negative, 14 (38%) stained weakly, 6 (16%) stained moderately, and 1 (3%) stained strongly. Of the 19 malignant PTs, 3 (16%) were negative, 4 (21%) stained weakly, 3 (16%) stained moderately, and 9 (47%) stained strongly. The mean intensity score for p53 staining increased progressively from benign to borderline to malignant PT, with established statistical significance (P < .0001). This is significantly correlated with mitotic count but not stromal cellularity, pleomorphism, margin, and stromal overgrowth. When considering strong staining alone (score, 3), 47% of malignant, 3% of borderline, and none of the benign PTs were positive. The use of strong positive staining for diagnosing malignant PT gave positive and negative predictive values, specificity, and sensitivity of 90%, 92.5%, 99%, and 47%, respectively. Thus diffuse strong p53 protein staining can be used as a soft sign in assisting the diagnosis of malignant PT. Conversely, negative or weak staining of p53 protein in PT is of little discriminatory value. The role of p53 gene mutation in the malignant transformation of PT is unclear; but this may not be the sole mechanism as many malignant PT were p53 protein negative.